Foreign-Trade Zone 59-Lincoln, Nebraska, Application for Temporary/Interim Manufacturing Authority, Novartis Consumer Health, Inc. (Pharmaceutical Product Manufacturing), Lincoln, NE, 4758-4759 [2012-2073]
Download as PDF
<![CDATA[
4758
Federal Register / Vol. 77, No. 20 / Tuesday, January 31, 2012 / Notices
Preliminary Issues
The project’s interdisciplinary team
has developed a list of preliminary
issues that will be used during the
analysis of effects. Other issues may
arise as a result of public comment and
further analysis. Preliminary issues
include:
• Invasive Plant Species (Noxious
Weeds). Several populations of noxious
weeds are known to exist within the
project area. There is a risk that
management activities may exacerbate
the weed situation by spreading existing
populations or introducing new ones.
• Peck’s Mariposa Lily. Management
activities can improve habitat for this
sensitive species, but also risk
impacting individual plants and/or
habitat where it occurs in the project
area.
• Soil Productivity. Maintenance of
soil productivity is an important
objective for management of National
Forest Lands. When mechanized
equipment is used in the Forest, soil can
become displaced and compacted,
which can impact productivity.
• Water Quality. The main streams in
the project area, McKay and Little
McKay Creeks, are listed on Oregon
DEQ’s 303(d) list due to high summer
temperatures. Management activities
can result in reduced shade on streams,
as well as contribute sediment into the
streams, which impacts water quality
and decreases habitat quality for fish
and other riparian fauna.
• Wildlife Habitat. Activities
intended to improve forest health and
resiliency may reduce habitat
effectiveness for some wildlife species,
including forest raptors and big game.
• Economics. In the current economy,
markets for wood products are severely
depressed. Some forest work is
extremely labor-intensive and the Forest
Service depends on these markets to pay
for the work that is needed to improve
forest health and reduce fuels.
wreier-aviles on DSK5TPTVN1PROD with NOTICES
Scoping Process
This notice of intent initiates the
scoping process, which guides the
development of the environmental
impact statement. At this time, the
Ochoco National Forest plans to hold a
public field trip to the project area in
the late spring or early summer of 2012;
details will be made public closer to
that time.
It is important that reviewers provide
their comments at such times and in
such manner that they are useful to the
agency’s preparation of the
environmental impact statement.
Therefore, comments should be
provided prior to the close of the
VerDate Mar<15>2010
15:20 Jan 30, 2012
Jkt 226001
comment period and should clearly
articulate the reviewer’s concerns and
contentions.
Comments received in response to
this solicitation, including names and
addresses of those who comment, will
be part of the public record for this
proposed action. Comments submitted
anonymously will be accepted and
considered.
Dated: January 25, 2012.
Slater R. Turner,
District Ranger.
[FR Doc. 2012–2009 Filed 1–30–12; 8:45 am]
BILLING CODE 3410–11–P
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[Docket T–2–2012]
Foreign-Trade Zone 59—Lincoln,
Nebraska, Application for Temporary/
Interim Manufacturing Authority,
Novartis Consumer Health, Inc.
(Pharmaceutical Product
Manufacturing), Lincoln, NE
An application has been submitted to
the Executive Secretary of the ForeignTrade Zones Board (the Board) by
Lincoln Foreign-Trade Zone, Inc.,
grantee of FTZ 59, requesting
temporary/interim manufacturing (T/
IM) authority at two sites within FTZ 59
at Novartis Consumer Health, Inc.
(Novartis) facilities, located in Lincoln,
Nebraska. The application was filed on
January 24, 2012.
The Novartis facilities (568
employees, capacity of 450 million
units/year) are located within FTZ 59, at
Sites 3 and 4, in Lincoln, Nebraska.
Under T/IM procedures, Novartis has
requested authority to produce over-thecounter (OTC) pharmaceutical products,
such as analgesics, cough/cold
medicine, antihistamines/
decongestants, and penicillin-based
antibiotics (HTSUS 3004.10, 3004.40,
3004.90—duty free). Foreign ingredients
that would be used in production
(representing 25% of the value of the
finished products) include: Menthol
(HTSUS 2906.11), ibuprofen (HTSUS
2916.39), sodium salicylate (HTSUS
2918.21), aspirin (HTSUS 2918.22),
terbinafine (HTSUS 2921.49),
diphenhydramine citrate (HTSUS
2922.19), diclofenac sodium (HTSUS
2922.49), acetaminophen (HTSUS
2924.29), tolnaftate (HTSUS 2930.20),
lansoprazole (HTSUS 2933.39),
loratadine (HTSUS 2933.39), pyrilamine
maleate (HTSUS 2933.39),
dextromethorphan HBr (HTSUS
2933.49), clemastine fumarate (HTSUS
PO 00000
Frm 00002
Fmt 4703
Sfmt 4703
2933.99), acesulfame K (HTSUS
2934.99), bensalkonium chloride
(HTSUS 3402.13), and microcrystalline
cellulose (HTSUS 3912.90). Duty rates
on these inputs range from duty free to
6.5%. T/IM authority could be granted
for a period of up to two years.
FTZ procedures could exempt
Novartis from customs duty payments
on the foreign components used in
export production. The company
anticipates that some 5–10 percent of
the plant’s shipments will be exported.
On its domestic sales, Novartis would
be able to choose the duty rates during
customs entry procedures that apply to
the OTC pharmaceutical products (duty
free) for the foreign inputs noted above.
Novartis would also be exempt from
duty payments on foreign materials that
become scrap or waste during the
production process.
In accordance with the Board’s
regulations, Diane Finver of the FTZ
Staff is designated examiner to evaluate
and analyze the facts and information
presented in the application and case
record and to report findings and
recommendations pursuant to Board
Orders 1347 and 1480.
Public comment is invited from
interested parties. Submissions (original
and 3 copies) shall be addressed to the
Board’s Executive Secretary at the
following address: Office of the
Executive Secretary, Foreign-Trade
Zones Board, U.S. Department of
Commerce, Room 2111, 1401
Constitution Ave. NW., Washington, DC
20230. The closing period for their
receipt is March 1, 2012.
Novartis has also submitted a request
to the FTZ Board for FTZ manufacturing
authority beyond a two-year period,
which may include additional products
and components. It should be noted that
the request for extended authority
would be docketed separately and
would be processed as a distinct
proceeding. Any party wishing to
submit comments for consideration
regarding the request for extended
authority would need to submit such
comments pursuant to the separate
notice that would be published for that
request.
A copy of the application will be
available for public inspection at the
Office of the Foreign-Trade Zones
Board’s Executive Secretary at the
address listed above, and in the
‘‘Reading Room’’ section of the Board’s
Web site, which is accessible via
www.trade.gov/ftz. For further
information, contact Diane Finver at
Diane.Finver@trade.gov or 202–482–
1367.
E:\FR\FM\31JAN1.SGM
31JAN1
Federal Register / Vol. 77, No. 20 / Tuesday, January 31, 2012 / Notices
Dated: January 24, 2012.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2012–2073 Filed 1–30–12; 8:45 am]
BILLING CODE P
DEPARTMENT OF COMMERCE
International Trade Administration
Initiation of Antidumping and
Countervailing Duty Administrative
Reviews and Requests for Revocation
in Part
Import Administration,
International Trade Administration,
Department of Commerce.
SUMMARY: The Department of Commerce
(‘‘the Department’’) has received
requests to conduct administrative
reviews of various antidumping and
countervailing duty orders and findings
with December anniversary dates. In
accordance with the Department’s
regulations, we are initiating those
administrative reviews. The Department
also received requests to revoke two
antidumping duty orders in part.
DATES: Effective Date: January 31, 2012.
FOR FURTHER INFORMATION CONTACT:
Brenda Waters, Office of AD/CVD
Operations, Customs Unit, Import
Administration, International Trade
Administration, U.S. Department of
Commerce, 14th Street and Constitution
Avenue NW., Washington, DC 20230,
telephone: (202) 482–4735.
SUPPLEMENTARY INFORMATION:
AGENCY:
wreier-aviles on DSK5TPTVN1PROD with NOTICES
Background
The Department has received timely
requests, in accordance with 19 CFR
351.213(b), for administrative reviews of
various antidumping and countervailing
duty orders and findings with December
anniversary dates. The Department also
received a timely request to revoke in
part the antidumping duty orders on
certain cased pencils from the People’s
Republic of China for two exporters, and
on honey from Argentina with respect to
four exporters.
All deadlines for the submission of
various types of information,
certifications, or comments or actions by
the Department discussed below refer to
the number of calendar days from the
applicable starting time.
Notice of No Sales
If a producer or exporter named in
this notice of initiation had no exports,
sales, or entries during the period of
review (‘‘POR’’), it must notify the
Department within 60 days of
publication of this notice in the Federal
Register. All submissions must be filed
VerDate Mar<15>2010
15:20 Jan 30, 2012
Jkt 226001
electronically at https://
iaaccess.trade.gov in accordance with
19 CFR 351.303. See Antidumping and
Countervailing Duty Proceedings:
Electronic Filing Procedures;
Administrative Protective Order
Procedures, 76 FR 39263 (July 6, 2011).
Such submissions are subject to
verification in accordance with section
782(i) of the Tariff Act of 1930, as
amended (‘‘Act’’). Further, in
accordance with 19 CFR
351.303(f)(3)(ii), a copy of each request
must be served on the petitioner and
each exporter or producer specified in
the request.
Respondent Selection
In the event the Department limits the
number of respondents for individual
examination for administrative reviews,
the Department intends to select
respondents based on U.S. Customs and
Border Protection (‘‘CBP’’) data for U.S.
imports during the POR. We intend to
release the CBP data under
Administrative Protective Order
(‘‘APO’’) to all parties having an APO
within seven days of publication of this
initiation notice and to make our
decision regarding respondent selection
within 21 days of publication of this
Federal Register notice. The
Department invites comments regarding
the CBP data and respondent selection
within five days of placement of the
CBP data on the record of the applicable
review.
In the event the Department decides
it is necessary to limit individual
examination of respondents and
conduct respondent selection under
section 777A(c)(2) of the Act:
In general, the Department has found
that determinations concerning whether
particular companies should be
‘‘collapsed’’ (i.e., treated as a single
entity for purposes of calculating
antidumping duty rates) require a
substantial amount of detailed
information and analysis, which often
require follow-up questions and
analysis. Accordingly, the Department
will not conduct collapsing analyses at
the respondent selection phase of this
review and will not collapse companies
at the respondent selection phase unless
there has been a determination to
collapse certain companies in a
previous segment of this antidumping
proceeding (i.e., investigation,
administrative review, new shipper
review or changed circumstances
review). For any company subject to this
review, if the Department determined,
or continued to treat, that company as
collapsed with others, the Department
will assume that such companies
continue to operate in the same manner
PO 00000
Frm 00003
Fmt 4703
Sfmt 4703
4759
and will collapse them for respondent
selection purposes. Otherwise, the
Department will not collapse companies
for purposes of respondent selection.
Parties are requested to (a) identify
which companies subject to review
previously were collapsed, and (b)
provide a citation to the proceeding in
which they were collapsed. Further, if
companies are requested to complete
the Quantity and Value Questionnaire
for purposes of respondent selection, in
general each company must report
volume and value data separately for
itself. Parties should not include data
for any other party, even if they believe
they should be treated as a single entity
with that other party. If a company was
collapsed with another company or
companies in the most recently
completed segment of this proceeding
where the Department considered
collapsing that entity, complete quantity
and value data for that collapsed entity
must be submitted.
Deadline for Withdrawal of Request for
Administrative Review
Pursuant to 19 CFR 351.213(d)(1), a
party that has requested a review may
withdraw that request within 90 days of
the date of publication of the notice of
initiation of the requested review. The
regulation provides that the Department
may extend this time if it is reasonable
to do so. In order to provide parties
additional certainty with respect to
when the Department will exercise its
discretion to extend this 90-day
deadline, interested parties are advised
that, with regard to reviews requested
on the basis of anniversary months on
or after August 2011, the Department
does not intend to extend the 90-day
deadline unless the requestor
demonstrates that an extraordinary
circumstance has prevented it from
submitting a timely withdrawal request.
Determinations by the Department to
extend the 90-day deadline will be
made on a case-by-case basis.
Separate Rates
In proceedings involving non-market
economy (‘‘NME’’) countries, the
Department begins with a rebuttable
presumption that all companies within
the country are subject to government
control and, thus, should be assigned a
single antidumping duty deposit rate. It
is the Department’s policy to assign all
exporters of merchandise subject to an
administrative review in an NME
country this single rate unless an
exporter can demonstrate that it is
sufficiently independent so as to be
entitled to a separate rate.
To establish whether a firm is
sufficiently independent from
E:\FR\FM\31JAN1.SGM
31JAN1
]]>Agencies
[Federal Register Volume 77, Number 20 (Tuesday, January 31, 2012)]
[Notices]
[Pages 4758-4759]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-2073]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF COMMERCE
Foreign-Trade Zones Board
[Docket T-2-2012]
Foreign-Trade Zone 59--Lincoln, Nebraska, Application for
Temporary/Interim Manufacturing Authority, Novartis Consumer Health,
Inc. (Pharmaceutical Product Manufacturing), Lincoln, NE
An application has been submitted to the Executive Secretary of the
Foreign-Trade Zones Board (the Board) by Lincoln Foreign-Trade Zone,
Inc., grantee of FTZ 59, requesting temporary/interim manufacturing (T/
IM) authority at two sites within FTZ 59 at Novartis Consumer Health,
Inc. (Novartis) facilities, located in Lincoln, Nebraska. The
application was filed on January 24, 2012.
The Novartis facilities (568 employees, capacity of 450 million
units/year) are located within FTZ 59, at Sites 3 and 4, in Lincoln,
Nebraska. Under T/IM procedures, Novartis has requested authority to
produce over-the-counter (OTC) pharmaceutical products, such as
analgesics, cough/cold medicine, antihistamines/decongestants, and
penicillin-based antibiotics (HTSUS 3004.10, 3004.40, 3004.90--duty
free). Foreign ingredients that would be used in production
(representing 25% of the value of the finished products) include:
Menthol (HTSUS 2906.11), ibuprofen (HTSUS 2916.39), sodium salicylate
(HTSUS 2918.21), aspirin (HTSUS 2918.22), terbinafine (HTSUS 2921.49),
diphenhydramine citrate (HTSUS 2922.19), diclofenac sodium (HTSUS
2922.49), acetaminophen (HTSUS 2924.29), tolnaftate (HTSUS 2930.20),
lansoprazole (HTSUS 2933.39), loratadine (HTSUS 2933.39), pyrilamine
maleate (HTSUS 2933.39), dextromethorphan HBr (HTSUS 2933.49),
clemastine fumarate (HTSUS 2933.99), acesulfame K (HTSUS 2934.99),
bensalkonium chloride (HTSUS 3402.13), and microcrystalline cellulose
(HTSUS 3912.90). Duty rates on these inputs range from duty free to
6.5%. T/IM authority could be granted for a period of up to two years.
FTZ procedures could exempt Novartis from customs duty payments on
the foreign components used in export production. The company
anticipates that some 5-10 percent of the plant's shipments will be
exported. On its domestic sales, Novartis would be able to choose the
duty rates during customs entry procedures that apply to the OTC
pharmaceutical products (duty free) for the foreign inputs noted above.
Novartis would also be exempt from duty payments on foreign materials
that become scrap or waste during the production process.
In accordance with the Board's regulations, Diane Finver of the FTZ
Staff is designated examiner to evaluate and analyze the facts and
information presented in the application and case record and to report
findings and recommendations pursuant to Board Orders 1347 and 1480.
Public comment is invited from interested parties. Submissions
(original and 3 copies) shall be addressed to the Board's Executive
Secretary at the following address: Office of the Executive Secretary,
Foreign-Trade Zones Board, U.S. Department of Commerce, Room 2111, 1401
Constitution Ave. NW., Washington, DC 20230. The closing period for
their receipt is March 1, 2012.
Novartis has also submitted a request to the FTZ Board for FTZ
manufacturing authority beyond a two-year period, which may include
additional products and components. It should be noted that the request
for extended authority would be docketed separately and would be
processed as a distinct proceeding. Any party wishing to submit
comments for consideration regarding the request for extended authority
would need to submit such comments pursuant to the separate notice that
would be published for that request.
A copy of the application will be available for public inspection
at the Office of the Foreign-Trade Zones Board's Executive Secretary at
the address listed above, and in the ``Reading Room'' section of the
Board's Web site, which is accessible via www.trade.gov/ftz. For
further information, contact Diane Finver at Diane.Finver@trade.gov or
202-482-1367.
[[Page 4759]]
Dated: January 24, 2012.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2012-2073 Filed 1-30-12; 8:45 am]
BILLING CODE P
